The Greater Cannabis Company, Inc. reported its financial results for the first quarter of 2026, revealing a net loss of $33,376, a significant improvement compared to a net loss of $103,511 in the same period of 2025. The company did not generate any revenue from product sales or consulting fees during this quarter, maintaining the same revenue figures as the previous year. Operating expenses decreased to $33,376 from $43,536, primarily due to a reduction in other operating expenses, which fell from $11,319 to $3,376. The company’s accumulated deficit increased to $5,025,333 as of March 31, 2026, compared to $4,991,957 at the end of the previous fiscal year.
In terms of balance sheet performance, total current assets rose to $1,439 from $815, while total current liabilities increased to $776,464 from $742,464. The company’s stockholders’ deficiency also widened to $775,025 from $741,649. The increase in liabilities was driven by a rise in accrued officers’ compensation, which grew from $470,350 to $500,350. The company’s cash balance at the end of the quarter was $1,439, up from $815 at the end of 2025.
Strategically, the Greater Cannabis Company has focused on its licensing agreement with Shaare Zedek Scientific Ltd. for a novel cannabinoid therapeutic aimed at treating various neuropsychiatric disorders. This partnership is expected to enhance the company’s research and development capabilities and align with its goal of commercializing innovative cannabinoid therapeutics. The company has shifted its business model away from e-commerce and advertising to concentrate on the development of cannabinoid-based therapies.
Operationally, the company has maintained a consistent employee headcount, with no significant changes reported in staffing levels. The company continues to explore opportunities for geographic expansion and product adoption, although specific metrics regarding customer counts or user statistics were not disclosed in the filing. The company’s management has indicated that they are focused on improving operational efficiencies and reducing costs to enhance profitability in the future.
Looking ahead, the Greater Cannabis Company acknowledges the inherent risks and uncertainties in its business operations, including the need for additional financing to support its growth plans. The company has not provided specific forward-looking revenue or profitability targets but emphasizes its commitment to advancing its cannabinoid therapeutic initiatives. Management cautions that actual results may differ materially from expectations due to various factors, including market conditions and operational challenges.
About Greater Cannabis Company, Inc.
The Greater Cannabis Company develops and commercializes cannabinoid therapeutics, focusing on innovative drug delivery platforms and neuropsychiatric treatments. It holds licenses for cannabinoid-based therapies targeting conditions like autism and Parkinson’s disease. The company operates in the medical cannabis sector, emphasizing research, clinical development, and strategic partnerships, with a business model centered on developing proprietary therapeutics and licensing technologies in a highly regulated industry.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.